Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Ahead of print

Issues

Validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to detect cannabinoids in whole blood and breath

Jacqueline A. HubbardORCID iD: https://orcid.org/0000-0003-4092-7153 / Breland E. Smith / Philip M. Sobolesky
  • Department of Pathology and Laboratory Medicine, Santa Clara Valley Medical Center, San Jose, CA, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Sollip Kim
  • Department of Laboratory Medicine, Inje University Ilsan Paik Hospital, Ilsan Seo-gu, Goyang, Republic of Korea
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Melissa A. Hoffman / Judith Stone
  • University of California, San Francisco Medical Center, Laboratory Medicine, Parnassus Chemistry, San Francisco, CA, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Marilyn A. Huestis
  • The Lambert Center for the Study of Medicinal Cannabis and Hemp, Institute for Emerging Health Professions, Thomas Jefferson University, Philadelphia, PA, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ David J. Grelotti / Igor Grant / Thomas S. Marcotte / Robert L. Fitzgerald
Published Online: 2019-09-17 | DOI: https://doi.org/10.1515/cclm-2019-0600

Abstract

Background

The widespread availability of cannabis raises concerns regarding its effect on driving performance and operation of complex equipment. Currently, there are no established safe driving limits regarding ∆9-tetrahydrocannabinol (THC) concentrations in blood or breath. Daily cannabis users build up a large body burden of THC with residual excretion for days or weeks after the start of abstinence. Therefore, it is critical to have a sensitive and specific analytical assay that quantifies THC, the main psychoactive component of cannabis, and multiple metabolites to improve interpretation of cannabinoids in blood; some analytes may indicate recent use.

Methods

A liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed to quantify THC, cannabinol (CBN), cannabidiol (CBD), 11-hydroxy-THC (11-OH-THC), (±)-11-nor-9-carboxy-Δ9-THC (THCCOOH), (+)-11-nor-Δ9-THC-9-carboxylic acid glucuronide (THCCOOH-gluc), cannabigerol (CBG), and tetrahydrocannabivarin (THCV) in whole blood (WB). WB samples were prepared by solid-phase extraction (SPE) and quantified by LC-MS/MS. A rapid and simple method involving methanol elution of THC in breath collected in SensAbues® devices was optimized.

Results

Lower limits of quantification ranged from 0.5 to 2 μg/L in WB. An LLOQ of 80 pg/pad was achieved for THC concentrations in breath. Calibration curves were linear (R2>0.995) with calibrator concentrations within ±15% of their target and quality control (QC) bias and imprecision ≤15%. No major matrix effects or drug interferences were observed.

Conclusions

The methods were robust and adequately quantified cannabinoids in biological blood and breath samples. These methods will be used to identify cannabinoid concentrations in an upcoming study of the effects of cannabis on driving.

This article offers supplementary material which is provided at the end of the article.

Keywords: breath; cannabis; LC-MS/MS; mass spectrometry; THC; whole blood

References

  • 1.

    The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. The National Academies Collection: Reports funded by National Institutes of Health. Washington, DC: National Institutes of Health, 2017.Google Scholar

  • 2.

    Ebbert JO, Scharf EL, Hurt RT. Medical cannabis. Mayo Clin Proc 2018;93:1842–7.CrossrefWeb of SciencePubMedGoogle Scholar

  • 3.

    Spindle TR, Bonn-Miller MO, Vandrey R. Changing landscape of cannabis: novel products, formulations, and methods of administration. Curr Opin Psychol 2019;30:98–102.CrossrefPubMedGoogle Scholar

  • 4.

    Kelley-Baker T, Berning A, Ramirez A, Lacey JH, Carr K, Waehrer G, et al. 2013–2014 National Roadside Study of alcohol and drug use by drivers: drug results (Report No. DOT HS 812 411). Washington, DC: National Highway Traffic Safety Administration, 2017.Google Scholar

  • 5.

    Broyd SJ, van Hell HH, Beale C, Yucel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition – a systematic review. Biol Psychiatry 2016;79:557–67.CrossrefWeb of SciencePubMedGoogle Scholar

  • 6.

    Compton R. Marijuana-impaired driving – a report to congress (DOT HS 812 440). Washington, DC: National Highway Traffic Safety Administration, 2017.Google Scholar

  • 7.

    Ramaekers JG, Berghaus G, van Laar M, Drummer OH. Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend 2004;73:109–19.PubMedCrossrefGoogle Scholar

  • 8.

    Biecheler M-B, Peytavin J-F, the SAMG, Facy F, Martineau H. SAM survey on “drugs and fatal accidents”: search of substances consumed and comparison between dInvolved under the influence of alcohol or cannabis. Traffic Injury Prev 2008;9:11–21.CrossrefGoogle Scholar

  • 9.

    Logan B, Kacinko SL, Beirness DJ. An evaluation of data from drivers arrested for driving under the influence in relation to per se limits for cannabis. AAA Foundation for Traffic Safety, 2016. https://aaafoundation.org/wp-content/uploads/2017/12/ EvaluationOfDriversInRelationToPerSeReport.pdf.

  • 10.

    Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney GR, et al. Effect of blood collection time on measured delta9-tetrahydrocannabinol concentrations: implications for driving interpretation and drug policy. Clin Chem 2016;62:367–77.PubMedCrossrefGoogle Scholar

  • 11.

    Schwope DM, Bosker WM, Ramaekers JG, Gorelick DA, Huestis MA. Psychomotor performance, subjective and physiological effects and whole blood Delta(9)-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. J Anal Toxicol 2012;36:405–12.CrossrefPubMedGoogle Scholar

  • 12.

    Hartman RL, Huestis MA. Cannabis effects on driving skills. Clin Chem 2013;59:478–92.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 13.

    Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RH, et al. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers’ blood on per se drugged driving laws. Clin Chem 2013;59:519–26.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 14.

    Newmeyer MN, Swortwood MJ, Barnes AJ, Abulseoud OA, Scheidweiler KB, Huestis MA. Free and glucuronide whole blood cannabinoids’ pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: identification of recent cannabis intake. Clin Chem 2016;62:1579–92.Web of ScienceCrossrefPubMedGoogle Scholar

  • 15.

    Scheidweiler KB, Schwope DM, Karschner EL, Desrosiers NA, Gorelick DA, Huestis MA. In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis. Clin Chem 2013;59:1108–17.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 16.

    Himes SK, Scheidweiler KB, Beck O, Gorelick DA, Desrosiers NA, Huestis MA. Cannabinoids in exhaled breath following controlled administration of smoked cannabis. Clin Chem 2013;59:1780–9.Web of SciencePubMedCrossrefGoogle Scholar

  • 17.

    Sobolesky PM, Smith BE, Hubbard JA, Stone J, Marcotte TD, Grelotti DJ, et al. Validation of a liquid chromatography-tandem mass spectrometry method for analyzing cannabinoids in oral fluid. Clin Chim Acta 2019;491:30–8.CrossrefWeb of SciencePubMedGoogle Scholar

  • 18.

    Rudzki PJ, Gniazdowska E, Bus-Kwasnik K. Quantitative evaluation of the matrix effect in bioanalytical methods based on LC-MS: a comparison of two approaches. J Pharm Biomed Anal 2018;155:314–9.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 19.

    Hadener M, Weinmann W, Schurch S, Konig S. Development of a rapid column-switching LC-MS/MS method for the quantification of THCCOOH and THCCOOH-glucuronide in whole blood for assessing cannabis consumption frequency. Anal Bioanal Chem 2016;408:1953–62.Web of SciencePubMedCrossrefGoogle Scholar

  • 20.

    Konig S, Aebi B, Lanz S, Gasser M, Weinmann W. On-line SPE LC-MS/MS for the quantification of Delta9-tetrahydrocannabinol (THC) and its two major metabolites in human peripheral blood by liquid chromatography tandem mass spectrometry. Anal Bioanal Chem 2011;400:9–16.PubMedCrossrefGoogle Scholar

  • 21.

    Palazzoli F, Citti C, Licata M, Vilella A, Manca L, Zoli M, et al. Development of a simple and sensitive liquid chromatography triple quadrupole mass spectrometry (LC-MS/MS) method for the determination of cannabidiol (CBD), Delta(9)-tetrahydrocannabinol (THC) and its metabolites in rat whole blood after oral administration of a single high dose of CBD. J Pharm Biomed Anal 2018;150:25–32.PubMedWeb of ScienceGoogle Scholar

  • 22.

    Schwope DM, Scheidweiler KB, Huestis MA. Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 2011;401:1273–83.Web of SciencePubMedCrossrefGoogle Scholar

  • 23.

    Teixeira H, Verstraete A, Proenca P, Corte-Real F, Monsanto P, Vieira DN. Validated method for the simultaneous determination of Delta9-THC and Delta9-THC-COOH in oral fluid, urine and whole blood using solid-phase extraction and liquid chromatography-mass spectrometry with electrospray ionization. Forensic Sci Int 2007;170:14–55.Google Scholar

  • 24.

    Tiscione NB, Miller R, Shan X, Sprague J, Yeatman DT. An efficient, robust method for the determination of cannabinoids in whole blood by LC-MS-MS. J Anal Toxicol 2016;40:639–48.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 25.

    Fell JC, Scherer M. Estimation of the potential effectiveness of lowering the blood alcohol concentration (BAC) limit for driving from 0.08 to 0.05 grams per deciliter in the United States. Alcohol Clin Exp Res 2017;41:2128–39.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 26.

    Lynch KL, Luo YR, Hooshfar S, Yun C. Correlation of breath and blood Delta(9)-tetrahydrocannabinol concentrations and release kinetics following controlled administration of smoked cannabis. Clin Chem 2019. pii: clinchem.2019.304501. doi: 10.1373/clinchem.2019.304501 [Epub ahead of print].Google Scholar

  • 27.

    Coucke L, Massarini E, Ostijn Z, Beck O, Verstraete AG. Delta(9)-Tetrahydrocannabinol concentrations in exhaled breath and physiological effects following cannabis intake – a pilot study using illicit cannabis. Clin Biochem 2016;49:1072–7.Web of ScienceCrossrefPubMedGoogle Scholar

  • 28.

    Beck O, Sandqvist S, Dubbelboer I, Franck J. Detection of Delta9-tetrahydrocannabinol in exhaled breath collected from cannabis users. J Anal Toxicol 2011;35:541–4.CrossrefPubMedGoogle Scholar

  • 29.

    Luo YR, Yun C, Lynch KL. Quantitation of cannabinoids in breath samples using a novel derivatization LC-MS/MS assay with ultra-high sensitivity. J Anal Toxicol 2019;43:331–9.CrossrefWeb of SciencePubMedGoogle Scholar

  • 30.

    Garzinsky AM, Walpurgis K, Krug O, Thevis M. Does oral fluid contribute to exhaled breath samples collected by means of an electret membrane? Drug Test Anal 2019. doi: 10.1002/dta.2597. [Epub ahead of print].PubMedGoogle Scholar

  • 31.

    Sorensen LK, Hasselstrom JB. Sensitive determination of cannabinoids in whole blood by LC-MS-MS after rapid removal of phospholipids by filtration. J Anal Toxicol 2017;41:382–91.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 32.

    Scheidweiler KB, Newmeyer MN, Barnes AJ, Huestis MA. Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry. J Chromatogr A 2016;1453:34–42.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 33.

    Hanisch S, Paulke A, Toennes SW. 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol glucuronide exhibits acyl-migration isomers. J Pharm Biomed Anal 2017;146:261–5.Web of ScienceCrossrefPubMedGoogle Scholar

About the article

Corresponding author: Jacqueline A. Hubbard, PhD, Department of Pathology, University of California, 10300 Campus Point Drive, San Diego, CA 92121, USA, E-mail: jahubbard@ucsd.edu


Received: 2019-06-13

Accepted: 2019-08-21

Published Online: 2019-09-17


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: This work was supported by the State of California via the Medical Marijuana Regulation and Safety Act (Assembly Bill 266). Additional support was provided by the Center for Medicinal Cannabis Research at the University of California, San Diego, which receives support from the Control, Regulate, and Tax Adult Use of Marijuana Act (California Proposition 64) and philanthropic gifts from the Wholistic Research and Education Foundation.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), 20190600, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2019-0600.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Supplementary Article Materials

Comments (0)

Please log in or register to comment.
Log in